{"transactions":[{"id":1478479,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T17:34:57.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":4570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":4570,"derivative":{"exercise_price":106.14,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001415889-24-016982","document":"form4-06142024_090653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924016982/form4-06142024_090653.xml","form_type":"4"}},{"id":1478478,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T17:34:57.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":2242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":58026,"source":{"system":"sec-edgar","filing":"0001415889-24-016982","document":"form4-06142024_090653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924016982/form4-06142024_090653.xml","form_type":"4"}},{"id":1844874,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T19:02:13.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":63.66,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-23-010257","document":"form4-06232023_110609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923010257/form4-06232023_110609.xml","form_type":"4"}},{"id":1844873,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T19:02:13.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":55784,"source":{"system":"sec-edgar","filing":"0001415889-23-010257","document":"form4-06232023_110609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923010257/form4-06232023_110609.xml","form_type":"4"}},{"id":2218486,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-30T21:56:30.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":50.64,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-22-007132","document":"form4-06302022_060618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922007132/form4-06302022_060618.xml","form_type":"4"}},{"id":2218485,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-30T21:56:30.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":53184,"source":{"system":"sec-edgar","filing":"0001415889-22-007132","document":"form4-06302022_060618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922007132/form4-06302022_060618.xml","form_type":"4"}},{"id":2256432,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-25T16:05:12.000Z","date":"2022-05-23","kind":"exercise","acquired":false,"shares":10909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2016 and is fully vested."}],"balance_after":0,"derivative":{"exercise_price":19.53,"expiration_date":"2026-06-23","underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001415889-22-005656","document":"form4-05252022_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922005656/form4-05252022_040501.xml","form_type":"4"}},{"id":2256431,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T16:05:12.000Z","date":"2022-05-23","kind":"exercise","acquired":true,"shares":10909,"price":19.53,"value":213052.77,"ownership":{"direct":true},"balance_after":50584,"source":{"system":"sec-edgar","filing":"0001415889-22-005656","document":"form4-05252022_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922005656/form4-05252022_040501.xml","form_type":"4"}},{"id":2680439,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:14:49.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022."}],"balance_after":4500,"derivative":{"exercise_price":87.13,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-21-006414","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911021006414/edgar.xml","form_type":"4"}},{"id":2680438,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T16:14:49.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":39675,"source":{"system":"sec-edgar","filing":"0001179110-21-006414","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911021006414/edgar.xml","form_type":"4"}},{"id":3012439,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T16:17:09.000Z","date":"2020-10-01","kind":"sale","acquired":false,"shares":1389,"price":92.06,"value":127871.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.89 to $92.24 per share."}],"balance_after":37425,"source":{"system":"sec-edgar","filing":"0001179110-20-010226","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020010226/edgar.xml","form_type":"4"}},{"id":3012438,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T16:17:09.000Z","date":"2020-10-01","kind":"sale","acquired":false,"shares":4530,"price":92.88,"value":420746.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.39 to $93.35 per share."}],"balance_after":38814,"source":{"system":"sec-edgar","filing":"0001179110-20-010226","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020010226/edgar.xml","form_type":"4"}},{"id":3012437,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T16:17:09.000Z","date":"2020-10-01","kind":"sale","acquired":false,"shares":3896,"price":93.68,"value":364977.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.36 to $94.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4."}],"balance_after":43344,"source":{"system":"sec-edgar","filing":"0001179110-20-010226","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020010226/edgar.xml","form_type":"4"}},{"id":3025692,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-21T16:21:20.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":500,"price":80,"value":40000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":47240,"source":{"system":"sec-edgar","filing":"0001179110-20-009900","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020009900/edgar.xml","form_type":"4"}},{"id":3086140,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-08T16:25:32.000Z","date":"2020-07-06","kind":"sale","acquired":false,"shares":600,"price":81.02,"value":48612.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.07 per share."}],"balance_after":47740,"source":{"system":"sec-edgar","filing":"0001179110-20-008109","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020008109/edgar.xml","form_type":"4"}},{"id":3086139,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-08T16:25:32.000Z","date":"2020-07-06","kind":"sale","acquired":false,"shares":25407,"price":80.44,"value":2043739.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.96 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":48340,"source":{"system":"sec-edgar","filing":"0001179110-20-008109","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020008109/edgar.xml","form_type":"4"}},{"id":3088160,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-06T18:30:41.000Z","date":"2020-07-02","kind":"sale","acquired":false,"shares":2825,"price":80.13,"value":226367.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.50 per share."}],"balance_after":73747,"source":{"system":"sec-edgar","filing":"0001104659-20-081384","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465920081384/a4.xml","form_type":"4"}},{"id":3088159,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-06T18:30:41.000Z","date":"2020-07-01","kind":"sale","acquired":false,"shares":1300,"price":80.21,"value":104273.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.03 to $80.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":76572,"source":{"system":"sec-edgar","filing":"0001104659-20-081384","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465920081384/a4.xml","form_type":"4"}},{"id":3098262,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-26T16:08:37.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021."}],"balance_after":4500,"derivative":{"exercise_price":76.24,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-20-007790","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007790/edgar.xml","form_type":"4"}},{"id":3098261,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-26T16:08:37.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":77872,"source":{"system":"sec-edgar","filing":"0001179110-20-007790","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007790/edgar.xml","form_type":"4"}},{"id":3099536,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-25T16:10:43.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":400,"price":80,"value":32000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":75622,"source":{"system":"sec-edgar","filing":"0001179110-20-007760","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007760/edgar.xml","form_type":"4"}},{"id":3101550,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T16:13:57.000Z","date":"2020-06-19","kind":"exercise","acquired":false,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-20-007717","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007717/edgar.xml","form_type":"4"}},{"id":3101549,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T16:13:57.000Z","date":"2020-06-22","kind":"sale","acquired":false,"shares":13017,"price":80.29,"value":1045134.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.96 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":76022,"source":{"system":"sec-edgar","filing":"0001179110-20-007717","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007717/edgar.xml","form_type":"4"}},{"id":3101548,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T16:13:57.000Z","date":"2020-06-19","kind":"exercise","acquired":true,"shares":1312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":89039,"source":{"system":"sec-edgar","filing":"0001179110-20-007717","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007717/edgar.xml","form_type":"4"}},{"id":3142082,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-19T16:31:29.000Z","date":"2020-05-15","kind":"gift","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":87727,"source":{"system":"sec-edgar","filing":"0001179110-20-006304","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020006304/edgar.xml","form_type":"4"}},{"id":3431741,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-21T16:18:22.000Z","date":"2019-08-19","kind":"gift","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":107727,"source":{"system":"sec-edgar","filing":"0001179110-19-009748","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019009748/edgar.xml","form_type":"4"}},{"id":3482164,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-20T16:37:24.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."}],"balance_after":1312,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-19-007984","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019007984/edgar.xml","form_type":"4"}},{"id":3482163,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T16:37:24.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":4875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."}],"balance_after":4875,"derivative":{"exercise_price":96.77,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0001179110-19-007984","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019007984/edgar.xml","form_type":"4"}},{"id":3487283,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T17:11:56.000Z","date":"2019-06-13","kind":"sale","acquired":false,"shares":25000,"price":90.36,"value":2259000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.90 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":127727,"source":{"system":"sec-edgar","filing":"0001179110-19-007778","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019007778/edgar.xml","form_type":"4"}},{"id":3489230,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T18:00:43.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":300,"price":81.96,"value":24588.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.90 to $82.07 per share."}],"balance_after":152727,"source":{"system":"sec-edgar","filing":"0001179110-19-007732","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019007732/edgar.xml","form_type":"4"}},{"id":3489229,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T18:00:43.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":2000,"price":82.45,"value":164900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.08 to $83.07 per share."}],"balance_after":153027,"source":{"system":"sec-edgar","filing":"0001179110-19-007732","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019007732/edgar.xml","form_type":"4"}},{"id":3489228,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T18:00:43.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":5200,"price":83.83,"value":435916.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.18 to $84.16 per share."}],"balance_after":155027,"source":{"system":"sec-edgar","filing":"0001179110-19-007732","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019007732/edgar.xml","form_type":"4"}},{"id":3489227,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T18:00:43.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":6300,"price":84.66,"value":533358.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.21 to $85.17 per share."}],"balance_after":160227,"source":{"system":"sec-edgar","filing":"0001179110-19-007732","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019007732/edgar.xml","form_type":"4"}},{"id":3489226,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T18:00:43.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":11200,"price":85.75,"value":960400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on March 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.18 to $86.17 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4."}],"balance_after":166527,"source":{"system":"sec-edgar","filing":"0001179110-19-007732","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019007732/edgar.xml","form_type":"4"}},{"id":3665490,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-02-11T22:31:50.000Z","date":"2019-02-08","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":6000,"derivative":{"exercise_price":68.89,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-19-009031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919119009031/doc4.xml","form_type":"4"}},{"id":3883809,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T16:56:23.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2019."}],"balance_after":29318,"derivative":{"exercise_price":69.79,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-18-009000","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911018009000/edgar.xml","form_type":"4"}},{"id":3960810,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-18T20:46:28.000Z","date":"2018-04-16","kind":"sale","acquired":false,"shares":2222,"price":90.2561,"value":200549.0542,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $89.93 to $90.69 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":271106,"source":{"system":"sec-edgar","filing":"0001209191-18-025382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/doc4.xml","form_type":"4"}},{"id":3960809,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-18T20:46:28.000Z","date":"2018-04-16","kind":"sale","acquired":false,"shares":2803,"price":89.4154,"value":250631.3662,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $88.91 to $89.87 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":273328,"source":{"system":"sec-edgar","filing":"0001209191-18-025382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/doc4.xml","form_type":"4"}},{"id":3960808,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-18T20:46:28.000Z","date":"2018-04-16","kind":"sale","acquired":false,"shares":4250,"price":88.2982,"value":375267.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $87.91 to $88.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":276131,"source":{"system":"sec-edgar","filing":"0001209191-18-025382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/doc4.xml","form_type":"4"}},{"id":3960807,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-18T20:46:28.000Z","date":"2018-04-16","kind":"sale","acquired":false,"shares":9425,"price":87.4632,"value":824340.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $86.91 to $87.895 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":280381,"source":{"system":"sec-edgar","filing":"0001209191-18-025382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/doc4.xml","form_type":"4"}},{"id":3960806,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-18T20:46:28.000Z","date":"2018-04-16","kind":"sale","acquired":false,"shares":1390,"price":86.1532,"value":119752.948,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $85.75 to $86.73 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":289806,"source":{"system":"sec-edgar","filing":"0001209191-18-025382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/doc4.xml","form_type":"4"}},{"id":3960805,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-18T20:46:28.000Z","date":"2018-04-16","kind":"sale","acquired":false,"shares":10310,"price":85.1107,"value":877491.317,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $84.75 to $85.74 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":291196,"source":{"system":"sec-edgar","filing":"0001209191-18-025382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/doc4.xml","form_type":"4"}},{"id":3960804,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-18T20:46:28.000Z","date":"2018-04-16","kind":"sale","acquired":false,"shares":2600,"price":84.1846,"value":218879.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $83.69 to $84.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":301506,"source":{"system":"sec-edgar","filing":"0001209191-18-025382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/doc4.xml","form_type":"4"}},{"id":4019126,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-02T17:15:28.000Z","date":"2018-02-28","kind":"sale","acquired":false,"shares":4613,"price":86.35,"value":398332.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.16 to $86.54 per share."}],"balance_after":177727,"source":{"system":"sec-edgar","filing":"0001179110-18-003315","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911018003315/edgar.xml","form_type":"4"}},{"id":4019125,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-02T17:15:28.000Z","date":"2018-02-28","kind":"sale","acquired":false,"shares":5527,"price":86.92,"value":480406.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.56 to $87.55 per share."}],"balance_after":182340,"source":{"system":"sec-edgar","filing":"0001179110-18-003315","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911018003315/edgar.xml","form_type":"4"}},{"id":4019124,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-02T17:15:28.000Z","date":"2018-02-28","kind":"sale","acquired":false,"shares":5264,"price":88.2,"value":464284.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.72 to $88.60 per share."}],"balance_after":187867,"source":{"system":"sec-edgar","filing":"0001179110-18-003315","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911018003315/edgar.xml","form_type":"4"}},{"id":4019123,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-02T17:15:28.000Z","date":"2018-02-28","kind":"sale","acquired":false,"shares":9596,"price":89.03,"value":854331.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.62 to $89.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through(5) to this Form 4."}],"balance_after":193131,"source":{"system":"sec-edgar","filing":"0001179110-18-003315","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911018003315/edgar.xml","form_type":"4"}},{"id":4046930,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock Warrant (right to buy)","published_at":"2018-02-20T21:08:50.000Z","date":"2018-02-15","kind":"exercise","acquired":false,"shares":16483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the warrant became exercisable for shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This warrant is exercisable at any time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the warrant became exercisable for shares of common stock."}],"balance_after":0,"derivative":{"exercise_price":4.55,"expiration_date":"2018-11-04","underlying":"Common Stock","underlying_shares":16843},"source":{"system":"sec-edgar","filing":"0001209191-18-011264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118011264/doc4.xml","form_type":"4"}},{"id":4046929,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-20T21:08:50.000Z","date":"2018-02-15","kind":"exercise","acquired":true,"shares":16483,"price":4.55,"value":74997.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the warrant became exercisable for shares of common stock."}],"balance_after":304106,"source":{"system":"sec-edgar","filing":"0001209191-18-011264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118011264/doc4.xml","form_type":"4"}},{"id":4073454,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-02-06T21:11:18.000Z","date":"2018-02-02","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":6000,"derivative":{"exercise_price":104.81,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-18-007830","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919118007830/doc4.xml","form_type":"4"}},{"id":4273208,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-23T16:25:10.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":10909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2018."}],"balance_after":21818,"derivative":{"exercise_price":46.02,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001179110-17-009521","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911017009521/edgar.xml","form_type":"4"}},{"id":4381937,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-16T17:37:33.000Z","date":"2017-03-14","kind":"sale","acquired":false,"shares":1400,"price":39.72,"value":55608.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.70 to $39.76 per share."}],"balance_after":202727,"source":{"system":"sec-edgar","filing":"0001179110-17-004740","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911017004740/edgar.xml","form_type":"4"}},{"id":4381936,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-16T17:37:33.000Z","date":"2017-03-14","kind":"sale","acquired":false,"shares":68600,"price":40.06,"value":2748116.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.80 to $40.78 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":204127,"source":{"system":"sec-edgar","filing":"0001179110-17-004740","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911017004740/edgar.xml","form_type":"4"}},{"id":4417012,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-02-28T23:54:41.000Z","date":"2017-02-24","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes fully exercisable on February 24, 2018."}],"balance_after":15000,"derivative":{"exercise_price":24.6,"expiration_date":"2027-02-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-015460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919117015460/doc4.xml","form_type":"4"}},{"id":4475034,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2017-01-31T21:49:32.000Z","date":"2017-01-31","kind":"exercise","acquired":false,"shares":67345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":67345},"source":{"system":"sec-edgar","filing":"0001209191-17-006404","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919117006404/doc4.xml","form_type":"4"}},{"id":4475033,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-01-31T21:49:32.000Z","date":"2017-01-31","kind":"exercise","acquired":false,"shares":55403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":55403},"source":{"system":"sec-edgar","filing":"0001209191-17-006404","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919117006404/doc4.xml","form_type":"4"}},{"id":4475032,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2017-01-31T21:49:32.000Z","date":"2017-01-31","kind":"exercise","acquired":false,"shares":80877,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":80877},"source":{"system":"sec-edgar","filing":"0001209191-17-006404","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919117006404/doc4.xml","form_type":"4"}},{"id":4475031,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-31T21:49:32.000Z","date":"2017-01-31","kind":"purchase","acquired":true,"shares":16666,"price":15,"value":249990.0,"ownership":{"direct":true},"balance_after":287623,"source":{"system":"sec-edgar","filing":"0001209191-17-006404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919117006404/doc4.xml","form_type":"4"}},{"id":4475030,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":89867,"kind":"person","name":"Lydon Nicholas","position":1,"cik":"0001639935","reported_name":"Lydon Nicholas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-31T21:49:32.000Z","date":"2017-01-31","kind":"exercise","acquired":true,"shares":203625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."}],"balance_after":270957,"source":{"system":"sec-edgar","filing":"0001209191-17-006404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000120919117006404/doc4.xml","form_type":"4"}}]}